Press Releases

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.”

BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.”

The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated with the development and... continue reading >>

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”

BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include... continue reading >>

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”

BUFFALO, NY- March 27, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”

In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong... continue reading >>

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”

BUFFALO, NY- March 25, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML... continue reading >>

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”

BUFFALO, NY- March 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”

In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang,... continue reading >>

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”

BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “From osimertinib to preemptive combinations.”

“Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to... continue reading >>

“[...] we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.”

BUFFALO, NY- March 18, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.”

In this new study, researchers Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama ... continue reading >>

Oncotarget is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2024, which convenes April 5-10 in San Diego, California.

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. 

Impact Journals will be participating as an exhibitor at the American Association for Cancer... continue reading >>

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”

BUFFALO, NY- March 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.”

In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from ... continue reading >>

“[...] these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”

BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.”

Sacituzumab govitecan (SG) is an ... continue reading >>

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [...]”

BUFFALO, NY- February 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.”... continue reading >>

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.”

BUFFALO, NY- February 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”

In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts,... continue reading >>

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”

BUFFALO, NY- February 21, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”

As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta,... continue reading >>

“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by evaluating patients with papillary thyroid cancer (PTC) from Finland [...]”

BUFFALO, NY- February 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage ... continue reading >>

“Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”

BUFFALO, NY- February 14, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.”

About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known ... continue reading >>

“[...] people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the development of oral, esophageal, and gastric cancers.”

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational... continue reading >>

“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”

BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

In this new paper, researchers Ashley... continue reading >>

“[...] fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”

BUFFALO, NY- February 5, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?”

In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Devi Ahilya... continue reading >>

“[...] this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”

BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.”

Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature ... continue reading >>

“An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.”

BUFFALO, NY- January 29, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.”

In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer ... continue reading >>

“[...] this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”

BUFFALO, NY- January 24, 2024 – A new case report was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.”

Osimertinib has been shown to be... continue reading >>

“[...] bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”

BUFFALO, NY- January 22, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.”

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal... continue reading >>

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”

BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.”

Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the... continue reading >>

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”

BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”

In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute myeloid leukemia (AML) — an aggressive cancer of... continue reading >>

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.”

BUFFALO, NY- January 10, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.”

Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted... continue reading >>

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.”

BUFFALO, NY- January 8, 2024 – A new review paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine.”

Transformation-associated recombination (TAR) cloning represents a unique... continue reading >>

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”

BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.”

In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer... continue reading >>